Novo Nordisk’s shock decision to oust its chief executive has resulted in the Ozempic maker once again becoming Europe’s ...

It’s the hot-shot fix that took Hollywood — and now high school — by storm. Ozempic and other so-called “miracle” weight-loss ...

Positive news from the laboratory was the wind beneath the wings of Novo Nordisk (NYSE: NVO) stock on Thursday. The ...

Novo Nordisk’s drugs are being linked to an eye condition that can cause vision loss, while health tech companies made CNBC’s ...

Novo Nordisk is progressing both subcutaneous and oral versions of amycretin into Phase III trials for patients with obesity ...

Activist hedge fund Parvus Asset Management is building a stake in Ozempic -maker Novo Nordisk as the drugmaker hunts for a ...

Denmark-based multinational pharmaceutical company Novo Nordisk will be making available in the Philippines within this year ...

Novo Nordisk's GLP-1 agonist semaglutide, used to treat diabetes and obesity, may cause a serious eye condition that can lead ...

Deep Apple is the latest biotech to be tapped by Novo Nordisk as the drugmaker aims to regain market share lost to Eli Lilly.

Denmark's Novo Nordisk is partnering with biotech company Deep Apple Therapeutics in a deal worth up to $812 million to ...

Women employed at Novo Nordisk A/S are now paid more on average than the men working at the maker of blockbuster drugs Wegovy ...

Novo Nordisk's Q1 showed robust sales/EPS growth, fueled by soaring GLP-1 demand in a multi-billion dollar market. Read why I ...